| Name | Title | Contact Details |
|---|---|---|
Aymii Couzelis |
Chief Information Officer | Profile |
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company`s founding team of MIT engineers and scientists are shaping the future of biologics delivery.
Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company`s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion`s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
Pharmacists Mutual Companies is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease.